Sage Therapeutics (SAGE) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic updates and forward-looking statements

• Received an unsolicited acquisition proposal from Biogen; board and advisors are reviewing the offer.

• Strategic restructuring in 2024 provides cash runway into mid-2027 and supports operational efficiency.

• Key 2025 milestones include ZURZUVAE growth, SAGE-319 data readout late 2025, and a decision on SAGE-324 by mid-2025.

• Partnership with Shionogi progressing in Asia, with regulatory filings for MDD in Japan and anticipated approval later this year.

• Sage emphasizes a value-driven, patient-first culture and aims to advance brain health through focused R&D and strategic collaborations.

Commercial performance and market expansion

• ZURZUVAE is the first and only FDA-approved oral treatment for PPD, with over 4,100 women treated by Q3 2024 and significant quarter-on-quarter growth.

• 90% brand awareness among target OB-GYNs and psychiatrists within a year of launch, with favorable commercial and Medicaid coverage.

• Over 70% of prescriptions are written by OB-GYNs, driving system-wide changes in screening and treatment practices.

• Joint sales force expansion and targeted media, social, and direct-to-consumer campaigns planned for 2025 to further drive adoption.

• Sage is committed to scaling ZURZUVAE’s success by broadening HCP engagement and enhancing patient and provider education.

Disease awareness and healthcare system impact

• Disease education and destigmatization efforts are expanding through media, social platforms, and influencer campaigns.

• ACOG guidelines specifically recommend ZURZUVAE for PPD, supporting rapid adoption and office-wide practice changes.

• System-wide change observed as OB-GYN offices increase screening and treatment rates after adopting ZURZUVAE.

• State-level policy progress, such as Illinois Medicaid adding ZURZUVAE to its preferred drug list without prior authorization.

• Ongoing efforts to educate both providers and patients to improve diagnosis and access.